Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients (MAGNA)

Sara Varea

Status and phase: Completed; Phase 3

Conditions: Seizures (Incl Subtypes); Brain Tumor

Treatments: Drug: Magnesium Sulfate; Other: Sodium Chloride

Study type: Interventional

Funder types: Other

Identifiers

NCT01601314

MAGNA

2011-006301-10 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to determine the relationship between magnesium sulphate administration and levels of S100B protein in serum of patients undergoing supratentorial brain parenchymal resection.

Enrollment: 55 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and females older than 18 years.
• Undergoing supratentorial parenchyma resection surgery.
• Capable of collaborate on probes and explorations included in the study.
• Signature the written informed consent form.

Exclusion criteria

• Life expectancy less than 12 months due to the suspected histological type of tumour.
• Hypothalamic-pituitary axis illness.
• Presence of Melanoma previously.
• Glomerular filtration rate less than 60 mL/min.
• Thyroid or parathyroid glands pathology.
• Myasthenia gravis.
• Respiratory depression.
• Pregnancy or breastfeeding.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

55 participants in 2 patient groups, including a placebo group

magnesium sulphate

Experimental group

Description:

The patients who are going to receive Magnesium Sulphate

Treatment:

Drug: Magnesium Sulfate

Control

Placebo Comparator group

Description:

Patients who are going to receive Sodium Chloride 0.9%

Treatment:

Other: Sodium Chloride